Skip to Content

Burzynski Research Institute Inc BZYR

Morningstar Rating
$0.04 0.00 (0.24%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BZYR is trading at a 50% discount.
Price
$0.04
Fair Value
$3.82
Uncertainty
Extreme
1-Star Price
$8.67
5-Star Price
$5.75
Economic Moat
Gcxq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BZYR is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.04
Day Range
$0.040.05
52-Week Range
$0.020.10
Bid/Ask
$0.04 / $0.05
Market Cap
$5.53 Mil
Volume/Avg
7,300 / 7,047

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees

Valuation

Metric
BZYR
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BZYR
Quick Ratio
0.22
Current Ratio
0.29
Interest Coverage
Quick Ratio
BZYR

Profitability

Metric
BZYR
Return on Assets (Normalized)
−62,719.05%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
BZYR

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSzbx$453.9 Bil
VRTX
Vertex Pharmaceuticals IncFxchb$90.4 Bil
REGN
Regeneron Pharmaceuticals IncWzwxn$88.1 Bil
SGEN
Seagen Inc Ordinary SharesGsrjzh$40.3 Bil
MRNA
Moderna IncNwmv$30.1 Bil
ARGX
argenx SE ADRFfzr$26.1 Bil
BNTX
BioNTech SE ADRCcxpb$23.6 Bil
ALNY
Alnylam Pharmaceuticals IncFcvffq$20.6 Bil
BMRN
Biomarin Pharmaceutical IncTkqsrbt$16.9 Bil
INCY
Incyte CorpXvmwtc$12.0 Bil